The Farnesyltransferase Inhibitors Tipifarnib and Lonafarnib Inhibit Cytokines Secretion in a Cellular Model of Mevalonate Kinase Deficiency

作者：Marcuzzi Annalisa^*; De Leo Luigina; Decorti Giuliana; Crovella Sergio; Tommasini Alberto; Pontillo Alessandra

来源：Pediatric Research, 2011, 70(1): 78-82.

DOI：10.1203/PDR.0b013e31821b581c

The shortage of geranylgeranyl-pyrophosphate (GGPP) was associated to an increased IL-1 beta release in the autoinflammatory syndrome mevalonate kinase deficiency (MKD), a rare inherited disease that has no specific therapy. Farnesyltransferase inhibitors (FTIs) act at the end of mevalonate pathway. Two FT Is, Tipifarnib (Tip) and Lonafarnib (Lon), were therefore evaluated as possible therapeutical choices for the treatment of MKD. FTIs could lead to a redirection of the limited available number of mevalonate intermediates preferentially to GGPP synthesis, eventually preventing the uncontrolled inflammatory response. The effect of Tip and Lon on intracellular cholesterol level (ICL) and on proinflammatory cytokines secretion was evaluated in a cellular model of MKD, chemically obtained treating RAW 264.7 cells with lovastatin (Lova) and alendronate (Ald). The combination of FTIs with the isoprenoid geraniol (GOH) was also tested both in this model and in monocytes isolated from MKD patients. Tip and Lon proved to revert the ICL lowering and to significantly reduce the lipopolysaccharide-induced cytokines secretion in Ald-Lova -RAW 264.7 cells. This anti-inflammatory effect was amplified combining the use of GOH with Fits. The effect of GOH and Tip was successfully replicated in MKD patients' monocytes. Tip and Lon showed a dramatic anti-inflammatory effect in monocytes where mevalonate pathway was chemically or genetically impaired. (Pediatr Res 70: 78-82, 2011)

• 出版日期2011-7